N-3C01

Phase I Primary Study Objective: Evaluate the tolerability and safety of N-3C01 monotherapy and its combination with PD-(L)1 monoclonal antibody subcutaneously in patients with advanced solid tumors, and determine the maximum tolerated dose (MTD) and the recommended dose for Phase II (RP2D). Phase I Secondary Study Objectives: Evaluate the pharmacokinetics and immunogenicity of N-3C01 monotherapy and its combination with PD-(L)1 monoclonal antibody subcutaneously in patients with advanced solid tumors. Phase I Exploratory Study Objective: Evaluate changes in biomarkers in patients with advanced solid tumors treated with N-3C01 monotherapy and its combination with PD-(L)1 monoclonal antibody subcutaneously. Phase II Primary Study Objective: Evaluate the efficacy of N-3C01 combined with PD-(L)1 monoclonal antibody subcutaneously at RP2D in selected patients with advanced solid tumors. Phase II Secondary Study Objectives: Evaluate the safety of N-3C01 combined with subcutaneous PD-(L)1 monoclonal antibody in selected patients with advanced solid tumors. Evaluate the pharmacokinetic and immunogenic characteristics of N-3C01 combined with subcutaneous PD-(L)1 monoclonal antibody in selected patients with advanced solid tumors. Phase II Exploratory Study Objectives: Evaluate changes in biomarkers in N-3C01 combined with subcutaneous PD-(L)1 monoclonal antibody in selected patients with advanced solid tumors.